Rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Document first published:
Page updated:
Topic:
Publication type:

Rituximab is recommended to be available as a routine commissioning treatment option for IgM paraproteinaemic demyelinating peripheral neuropathy in adults within the criteria set out in these documents.

Document

Clinical commissioning policy: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Clinical commissioning policy: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 285 KB
  • 10 pages

Document

Evidence review: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Evidence review: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 282 KB
  • 38 pages

Document

Engagement report: rituximab in the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Engagement report: rituximab in the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 84 KB
  • 6 pages

Document

Equality and health inequalities impact assessment: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Equality and health inequalities impact assessment: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 94 KB
  • 12 pages

Document

Clinical Priorities Advisory Group report: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Clinical Priorities Advisory Group report: rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 117 KB
  • 8 pages

Document

Clinical Panel report (Jan 2021): rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Clinical Panel report (Jan 2021): rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 36 KB
  • 3 pages

Document

Clinical Panel report (March 2021): rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

Clinical Panel report (March 2021): rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults

  • PDF
  • 34 KB
  • 3 pages